Vaccine News and Research

Latest Vaccine News and Research

As covid infections rise, nursing homes are still waiting for vaccines

"Covid is not pretty in a nursing home," said Deb Wityk, a 70-year-old retired massage therapist who lives in one called Spurgeon Manor, in rural Iowa. She twice contracted the disease and is eager to get the newly approved vaccine because she has chronic lymphocytic leukemia, which weakens her immune system.

27 Sep 2023

Zoonotic spillover safeguarding: computationally designed antigen targets range of coronaviruses

Researchers used an interdisciplinary approach incorporating phylogenetics, 3D protein modeling, and plasmid design to identify and computationally design an antigen representing the core of most currently known sarbecoviruses.

27 Sep 2023

Could baseline gut microbiota predict the immune responses elicited by COVID-19 vaccines?

Researchers characterized the gut microbiota composition associated with the durability of COVID-19 vaccine-induced immunity.

27 Sep 2023

New form of cellular immunotherapy shows promise against brain tumors in mice

Scientists from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) successfully tested a new form of cellular immunotherapy against brain tumors in mice for the first time.

26 Sep 2023

Monkeypox mimics smallpox vaccine's immune response, new study reveals

The study in Nature Communications reveals that MPOX infection triggers an anti-viral antibody response akin to that from smallpox vaccination. Utilizing a comprehensive array of ELISAs, scientists found a high level of specificity and sensitivity in detecting antibodies against both MPOX and smallpox, offering a new, accurate way to measure immune responses.

26 Sep 2023

Intranasal vaccine shows promise against COVID variants in hamsters

Intranasal mRNA-LNP vaccines show promise in Syrian golden hamsters, effectively reducing SARS-CoV-2 viral loads and lung pathology. The study suggests potential efficacy against new variants, setting the stage for future research in human applications.

25 Sep 2023

COVID drug molnupiravir appears to be driving SARS-CoV-2 to mutate and evolve

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.

25 Sep 2023

Future-proof vaccine candidate protects against wide range of coronaviruses

Studies of a 'future-proof' vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals.

25 Sep 2023

Cellular crosstalk between mother and offspring is more complex than expected

Scientists have known for decades that pregnancy requires a mother's body to adjust so that her immune system does not attack the growing fetus as if it were a hostile foreign invader.

22 Sep 2023

Peptide vaccine targets H3K27M mutation in midline gliomas, shows promise in early trials

Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are carrying cancer-typical alterations.

22 Sep 2023

Discovery lead to better methods for reducing mosquito-to-human transmission of deadly viruses

Researchers from the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health have made an important finding about Aedes aegypti mosquitoes - one that could one day lead to better methods for reducing the mosquito-to-human transmission of dengue, yellow fever, Zika, and other harmful and sometimes deadly viruses.

22 Sep 2023

VAX-seq: the future of mRNA vaccine analysis and quality assurance?

Researchers proposed a simplified approach for analyzing mRNA vaccines using long-read sequencing.

22 Sep 2023

Can COVID-19 vaccines turn the tide on long-haul symptoms?

The study finds that COVID-19 vaccination can significantly reduce symptoms and improve well-being in patients suffering from post-COVID-19 conditions (PCC). Vaccination also lowered systemic markers of inflammation but did not entirely eliminate persistent SARS-CoV-2 antigens, which may continue to contribute to inflammation.

22 Sep 2023

Inhaled fluticasone furoate falls flat in speeding up COVID-19 recovery, says ACTIV-6 trial

The ACTIV-6 trial investigated the effectiveness of inhaled fluticasone furoate on mild-to-moderate COVID-19 cases and found it did not accelerate recovery or prevent clinical progression compared to a placebo. Interestingly, vaccinated participants showed slightly faster recovery when treated with the drug, while unvaccinated participants did not.

21 Sep 2023

Nanoparticle vaccine may offer safe and effective protection against Dabie Bandavirus

Cleveland Clinic researchers have used nanoparticles to develop a potential vaccine candidate against Dabie Bandavirus, formerly known as Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), a tick-borne virus that currently has no prevention, treatment or cure.

21 Sep 2023

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

21 Sep 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023